377 related articles for article (PubMed ID: 1556650)
1. Potential of doxorubicin as an antileishmanial agent.
Sett R; Basu N; Ghosh AK; Das PK
J Parasitol; 1992 Apr; 78(2):350-4. PubMed ID: 1556650
[TBL] [Abstract][Full Text] [Related]
2. Antileishmanial activity of nano-amphotericin B deoxycholate.
Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
[TBL] [Abstract][Full Text] [Related]
3. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani.
Bories C; Cojean S; Huteau F; Loiseau PM
Biomed Pharmacother; 2008 Mar; 62(3):164-7. PubMed ID: 18249083
[TBL] [Abstract][Full Text] [Related]
4. Antiparasitic activity of a triphenyl tin complex against Leishmania donovani.
Raychaudhury B; Banerjee S; Gupta S; Singh RV; Datta SC
Acta Trop; 2005 Jul; 95(1):1-8. PubMed ID: 15896700
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
6. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis.
Mukherjee S; Das L; Kole L; Karmakar S; Datta N; Das PK
J Infect Dis; 2004 Mar; 189(6):1024-34. PubMed ID: 14999606
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
8. Antileishmanial effect of cisplatin against murine visceral leishmaniasis.
Kaur S; Sachdeva H; Dhuria S; Sharma M; Kaur T
Parasitol Int; 2010 Mar; 59(1):62-9. PubMed ID: 19853668
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
10. Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo.
Morishige K; Aji T; Ishii A; Yasuda T; Wataya Y
Exp Parasitol; 1995 Jun; 80(4):665-71. PubMed ID: 7758547
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
12. Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).
Yang M; Arai C; Bakar Md A; Lu J; Ge JF; Pudhom K; Takasu K; Kasai K; Kaiser M; Brun R; Yardley V; Itoh I; Ihara M
J Med Chem; 2010 Jan; 53(1):368-73. PubMed ID: 19894726
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.
Seifert K; Escobar P; Croft SL
J Antimicrob Chemother; 2010 Mar; 65(3):508-11. PubMed ID: 20089542
[TBL] [Abstract][Full Text] [Related]
14. Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
Charan Raja MR; Velappan AB; Chellappan D; Debnath J; Kar Mahapatra S
Eur J Med Chem; 2017 Oct; 139():503-518. PubMed ID: 28826085
[TBL] [Abstract][Full Text] [Related]
15. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
16. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
17. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
[TBL] [Abstract][Full Text] [Related]
18. Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis.
Kansal S; Tandon R; Dwivedi P; Misra P; Verma PR; Dube A; Mishra PR
J Antimicrob Chemother; 2012 Nov; 67(11):2650-60. PubMed ID: 22872448
[TBL] [Abstract][Full Text] [Related]
19. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
20. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
